Patents by Inventor Edith Pfitzner

Edith Pfitzner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Test system for measuring the interaction of STAT 6 with NCoA-1
    Patent number: 7585638
    Abstract: The present invention relates to a method to identify substances and a use of such substances which can modulate IL-4 dependent signaling involved in tumor diseases, preferably Hodgkin Lymphomas or inflammatory airway diseases, preferably asthma and a method for determining whether a substance can modulate the interaction of STAT6 with NCoA-1, characterized in that a) STAT6 or fragments or derivatives thereof having the ability to bind to NcoA-1 are brought into contact with NCoA-1 or fragments or derivatives of NCoA-1 having the ability to bind STAT6 under conditions where STAT6 and NCoA-1 or said fragments or derivatives are capable of forming a complex, and said complex can be used to induce a measurable readout; b) a readout is measured in the absence or presence of the substance of interest; c) the readout in absence of substance of interest is compared with readout in presence of substance of interest.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: September 8, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Claudia Monika Litterst, Edith Pfitzner
  • Test System for Measuring the Interaction of STAT 6 with NCoA-1
    Publication number: 20070202541
    Abstract: The present invention relates to a method to identify substances and a use of such substances which can modulate IL-4 dependent signaling involved in tumor diseases, preferably Hodgkin Lymphomas or inflammatory airway diseases, preferably asthma and a method for determining whether a substance can modulate the interaction of STAT6 with NCoA-1, characterized in that a) STAT6 or fragments or derivatives thereof having the ability to bind to NcoA-1 are brought into contact with NCoA-1 or fragments or derivatives of NCoA-1 having the ability to bind STAT6 under conditions where STAT6 and NCoA-1 or said fragments or derivatives are capable of forming a complex, and said complex can be used to induce a measurable readout; b) a readout is measured in the absence or presence of the substance of interest; c) the readout in absence of substance of interest is compared with readout in presence of substance of interest.
    Type: Application
    Filed: April 27, 2007
    Publication date: August 30, 2007
    Inventors: Edith Pfitzner, Claudia Litterst
  • Method of identifying substances which modulate interleukin 4(IL-4) signaling
    Patent number: 7226747
    Abstract: The present invention relates to a method to identify substances and a use of such substances which can modulate IL-4 dependent signaling involved in tumor diseases, preferably Hodgkin Lymphomas or inflammatory airway diseases, preferably asthma and a method for determining whether a substance can modulate the interaction of STAT6 with NCoA-1, characterized in that a) STAT6 or fragments or derivatives thereof having the ability to bind to NcoA-1 are brought into contact with NCoA-1 or fragments or derivatives of NCoA-1 having the ability to bind STAT6 under conditions where STAT6 and NCoA-1 or fragments or derivatives thereof are capable of forming a complex, and the complex can be used to induce a measurable readout; b) a readout is measured in the absence or presence of the substance of interest; c) the readout in absence of substance of interest is compared with readout in presence of substance of interest.
    Type: Grant
    Filed: July 8, 2002
    Date of Patent: June 5, 2007
    Assignee: Boehringer Ingelheim Corporation
    Inventors: Edith Pfitzner, Claudia Monika Litterst
  • Method of identifying substances which modulate interleukin 4(IL-4) signaling
    Publication number: 20030092619
    Abstract: The present invention relates to a method to identify substances and a use of such substances which can modulate IL-4 dependent signaling involved in tumor diseases, preferably Hodgkin Lymphomas or inflammatory airway diseases, preferably asthma and a method for determining whether a substance can modulate the interaction of STAT6 with NCoA-1, characterized in that
    Type: Application
    Filed: July 8, 2002
    Publication date: May 15, 2003
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Edith Pfitzner, Claudia Monika Litterst